Linden Thomas Advisory Services’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
LMFP
AIM
FWIA
DLA
Linden Thomas Advisory Services's BMY Position: Q2 2026 in Review
Linden Thomas Advisory Services increased its Bristol-Myers Squibb (BMY) stake by 2.6% in Q2 2026, buying an estimated $45.1K and bringing the position to 30,618 shares worth $1.76M. The position accounts for 0.14% of the portfolio, ranked #251.
Linden Thomas Advisory Services first reported a position in BMY in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.31M in Q1 2024. 796 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Linden Thomas Advisory Services held 30,618 shares of Bristol-Myers Squibb worth $1.76M as of Q2 2026.
- Linden Thomas Advisory Services bought 785 Bristol-Myers Squibb shares in Q2 2026, an estimated $45.1K.
- Bristol-Myers Squibb made up 0.14% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #251 holding.
- Linden Thomas Advisory Services first reported a position in Bristol-Myers Squibb in Q4 2022 and has held it in 15 quarters since.
- Linden Thomas Advisory Services's Bristol-Myers Squibb position peaked at $2.31M in Q1 2024.
- 796 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.